Abstract
Cagrilintide is a long-acting amylin analog peptide engineered to mimic the function of amylin, a hormone normally released alongside insulin by pancreatic beta cells. Unlike incretin-based therapies, cagrilintide acts primarily on amylin and calcitonin receptors in the brain, offering a complementary pathway for appetite suppression and metabolic regulation.
Molecular Background
Key characteristics of cagrilintide:
- Long-acting amylin analog with extended half-life
- Molecular modifications enhance stability and reduce enzymatic breakdown
- Supports once-weekly subcutaneous administration
- Currently under clinical investigation (not yet FDA-approved)
Mechanism of Action
Cagrilintide operates through distinct pathways from GLP-1 agonists:
- Amylin Receptor Activation: Enhances satiety signaling in the brain
- Calcitonin Receptor: Additional receptor target for appetite modulation
- Gastric Emptying: Prolongs gastric transit time for sustained fullness
- Meal Termination: Promotes earlier cessation of eating
- Craving Reduction: Decreases desire for high-fat and high-sugar foods
Clinical Research Summary
Data from published clinical trials (REDEFINE program):
- Monotherapy: 5-10% body weight loss compared to placebo
- Combination with Semaglutide: Up to 15% weight reduction
- Secondary Outcomes: Reduced waist circumference, visceral fat mass, and appetite scores
- Adherence: Once-weekly dosing improves patient compliance
Synergy with GLP-1 Agonists
When paired with semaglutide, cagrilintide creates a dual-pathway approach targeting both incretin and amylin networks. Clinical trials show enhanced outcomes when both peptides are combined:
- Greater total weight loss than either peptide alone
- Improved satiety and reduced food cravings
- Potential solution for GLP-1-resistant patients
- Overlapping side effects require careful titration
Safety Profile
Common side effects observed in clinical trials:
- Nausea: Mild to moderate, typically during initial titration phase
- Reduced Appetite: Therapeutic goal but may cause inadequate caloric intake
- Bloating: Related to delayed gastric emptying
- Vomiting: Associated with rapid dose escalation
Contraindications
- Medullary Thyroid Carcinoma: Due to calcitonin receptor activity
- MEN2 Syndrome: Receptor overlap with calcitonin pathways
- Severe GI Conditions: Gastroparesis, chronic dysmotility
- Pregnancy/Breastfeeding: Insufficient safety data
- Severe Renal Impairment: eGFR less than 30 mL/min/1.73 m²
Comparison: Cagrilintide vs Semaglutide
| Feature | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor Target | Amylin/Calcitonin | GLP-1 |
| Administration | Weekly SC injection | Weekly SC injection |
| FDA Status | Investigational | Approved |
| Best Use | Combination therapy | Monotherapy or combo |
Current Research Status
Cagrilintide remains under clinical investigation and is not yet FDA-approved. Ongoing studies are assessing long-term cardiovascular outcomes, weight loss durability, and real-world adherence. If approved, cagrilintide could become a first-line option in combination with GLP-1 agonists for patients with obesity-related conditions.